24 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 28 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 28 | Completed 24, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Solitary Fibrous Tumors: new trials by email Literature Review of Solitary Fibrous Tumors trials Research Report on Solitary Fibrous Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Oral repotrectinib (TPX-0005) - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Turning Point Therapeutics, Inc. | 75 | 2020-03-12 | 2026-09-25 |
| Eribulin in Advanced Solitary Fibrous Tumor Eribulin - Solitary Fibrous Tumor | Phase 2 | Completed | Italian Sarcoma Group | 16 | 2019-07-17 | 2024-09-20 |
| Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor Trabectedin, Adriamycin, Dacarbazine - Solitary Fibrous Tumors | Phase 2 | Completed | Italian Sarcoma Group | 23 | 2018-03-04 | 2024-12-09 |
| Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin - Soft Tissue Sarcoma, Bone Sarcoma | Phase 1 / Phase 2 | Completed | Grupo Espanol de Investigacion en Sarcomas | 197 | 2017-05-31 | 2024-08-13 |
| Pembrolizumab in Treating Patients With Malignant Mesothelioma Pembrolizumab, Laboratory Biomarker Analysis, Pharmacogenomic Study - Biphasic Mesothelioma, Epithelioid Mesothelioma | Phase 2 | Completed | University of Chicago | 65 | 2015-03-31 | 2026-05-08 |
| Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor Axitinib - Solitary Fibrous Tumor | Phase 2 | Completed | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 17 | 2014-11-01 | 2021-09-28 |
| Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma Pazopanib - Solitary Fibrous Tumor, Extraskeletal Myxoid Chondrosarcoma | Phase 2 | Completed | Grupo Espanol de Investigacion en Sarcomas | 96 | 2014-06-01 | 2023-03-27 |
| Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma Laboratory Biomarker Analysis, Tivantinib - Epithelioid Mesothelioma, Recurrent Malignant Mesothelioma | Phase 2 | Terminated | National Cancer Institute (NCI) | 18 | 2013-01-01 | 2016-10-24 |
| Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy pemetrexed disodium, clinical observation - Malignant Mesothelioma | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 72 | 2010-04-01 | 2021-08-18 |
| AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma rilotumumab, cisplatin, pemetrexed disodium - Advanced Malignant Mesothelioma, Epithelial Mesothelioma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2010-04-01 | 2013-08-02 | |
| Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Cediranib Maleate, Cisplatin, Laboratory Biomarker Analysis - Epithelioid Mesothelioma, Pleural Malignant Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 117 | 2010-03-15 | 2026-10-22 |
| Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma dasatinib - Malignant Mesothelioma | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 46 | 2007-08-01 | 2016-08-11 |
| Trial of Dasatinib in Advanced Sarcomas Dasatinib - Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 366 | 2007-05-01 | 2018-11-23 |
| PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery belinostat, laboratory biomarker analysis - Advanced Malignant Mesothelioma, Epithelial Mesothelioma | Phase 2 | Completed | National Cancer Institute (NCI) | 13 | 2006-06-01 | 2018-06-07 |
| Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery cediranib maleate - Advanced Malignant Mesothelioma, Epithelial Mesothelioma | Phase 2 | Completed | National Cancer Institute (NCI) | 51 | 2005-12-01 | 2014-07-31 |
| Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Cisplatin, Pemetrexed, Therapeutic conventional surgery - Malignant Mesothelioma | Phase 2 | Completed | Swiss Cancer Institute | 153 | 2005-11-14 | 2019-05-15 |
| S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery cediranib maleate, laboratory biomarker analysis - Advanced Malignant Mesothelioma, Epithelial Mesothelioma | Phase 2 | Completed | National Cancer Institute (NCI) | 54 | 2005-11-01 | 2018-01-23 |
| Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma cisplatin, pemetrexed disodium, adjuvant therapy - Malignant Mesothelioma | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 59 | 2005-07-01 | 2012-07-18 |
| Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. sorafenib tosylate, laboratory biomarker analysis - Epithelial Mesothelioma, Recurrent Malignant Mesothelioma | Phase 2 | Completed | National Cancer Institute (NCI) | 44 | 2004-10-01 | 2013-06-05 |
| PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma PTK787/ZK 222584 - Malignant Mesothelioma | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 47 | 2003-07-01 | 2016-07-01 |
Showing 20 of 28. Sign in to see all of them.
Mesothelioma, Malignant (21) · Solitary Fibrous Tumor, Pleural (21) · Sarcoma (4) · Chondrosarcoma (2) · Chondrosarcoma, Extraskeletal Myxoid (2) · Neoplasm Metastasis (2) · Sarcoma, Alveolar Soft Part (2) · Sarcoma, Ewing (2) · Bone Neoplasms (1) · Chordoma (1) · Gastrointestinal Stromal Tumors (1) · Giant Cell Tumor of Bone (1) · Glioblastoma (1) · Glioma (1)
Neoplasms (28) · Neoplasms by Histologic Type (28) · Neoplasms, Connective Tissue (28) · Neoplasms, Connective and Soft Tissue (28) · Neoplasms, Fibrous Tissue (28) · Neoplasms by Site (22) · Neoplasms, Glandular and Epithelial (22) · Adenoma (21) · Lung Diseases (21) · Lung Neoplasms (21) · Mesothelioma (21) · Neoplasms, Mesothelial (21) · Pleural Neoplasms (21) · Respiratory Tract Diseases (21) · Respiratory Tract Neoplasms (21)
Cisplatin (7) · Pemetrexed (5) · Chemotherapy, Adjuvant (3) · cediranib (3) · Dacarbazine (2) · Dasatinib (2) · Doxorubicin (2) · Gemcitabine (2) · Methotrexate (2) · Neoadjuvant Therapy (2) · Radiotherapy (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · ARQ 197 (1) · Axitinib (1) · Bevacizumab (1)
National Cancer Institute (NCI) (11) · Alliance for Clinical Trials in Oncology (4) · Grupo Espanol de Investigacion en Sarcomas (2) · Italian Sarcoma Group (2) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Roswell Park Cancer Institute (1) · SWOG Cancer Research Network (1) · Sarcoma Alliance for Research through Collaboration (1) · Swiss Cancer Institute (1) · The Cleveland Clinic (1) · Turning Point Therapeutics, Inc. (1) · University of Chicago (1)
United States (20) · Italy (6) · Spain (3) · United Kingdom (3) · Australia (1) · Belgium (1) · Canada (1) · Denmark (1) · France (1) · Germany (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Switzerland (1) · Taiwan (1)
Hedy Kindler (4) · Silvia Stacchiotti, MD (4) · Arkadiusz Dudek, MD (2) · Linda Garland (2) · Alba Rubio (1) · Anne S Tsao (1) · Antonio Casado (1) · Claudia Valverde (1) · Cristina Mata (1)
PMID 15084390, PMID 18006112, PMID 20525721, PMID 21684151, PMID 22197613, PMID 22831987, PMID 26538423, PMID 30578023, PMID 31331701, PMID 31386610, PMID 31401903, PMID 32066540, PMID 33203665, PMID 34814185, PMID 35965642, PMID 39356980, PMID 41836677
U10CA031946 (6), U10CA032102 (4), P30CA014599 (3), N01CM17102 (2), 2004 (1), 2023 (1), N01CM00071 (1), N01CM62209 (1), P30CA043703 (1), U10CA021115 (1), U10CA180821 (1), U10CA180830 (1), U10CA180888 (1)